Marinus Pharmaceuticals Inc (FRA:61Y)
€ 0.302 0.002 (0.67%) Market Cap: 17.09 Mil Enterprise Value: 30.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Marinus Pharmaceuticals Inc at American Epilepsy Society Annual Meeting Transcript

Dec 05, 2022 / 02:30PM GMT
Release Date Price: €4.36 (-0.46%)
Sasha Damouni Ellis
Marinus Pharmaceuticals, Inc. - VP of Corporate Affairs & IR

Okay, we're going to get started this morning. Alright. So good morning, everyone. Thank you for joining today. We're very excited to have our first in-person and virtual AES Investor Breakfast. I would like to take a moment just to go over our safe harbor statement before proceeding to today's agenda.

Okay, on to the agenda, we have quite a few folks here, a lot of new faces. So if we just start at the top, we have our Senior Vice President, Scientific Affairs, Alex Aimetti, who will provide a 2-year analysis of safety and effectiveness of Ganaxolone in patients with CDKL5 deficiency disorder. We'll turn to Dr. Ian Miller, Vice President of Clinical Affairs, who will discuss data that we presented at AES on our results of our TSC drug-drug interaction study with cannabinoids. Dr. Joe Hulihan, our Chief Medical Officer (inaudible) pro drug efforts and next steps.

Then, we'll turn over to our commercial group, where our Chief Commercial Officer, Christy Shafer, will discuss our early launch and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot